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Abstract.
Background: Duchenne Muscular Dystrophy (DMD) is a recessive X-linked form of muscular dystrophy. Steroid therapy has
clinical benefits for DMD patients, but the mechanism remains unclear.
Objective: This study was designed to identify mRNAs and microRNAs regulated in Duchenne Muscular Dystrophy patients
prior to and after steroid therapy.
Methods: Genome wide transcriptome profiling of whole blood was performed to identify mRNAs and microRNAs regulated
in DMD patients.
Results: The data show many regulated mRNAs and some microRNAs, including some muscle-specific microRNAs (e.g.,
miR-206), that were significantly altered in blood of young (age 3–10) DMD patients compared to young controls. A total of 95
microRNAs, but no mRNAs, were differentially expressed in older DMD patients compared to matched controls (age 11–20).
Steroid treatment reversed expression patterns of several microRNAs (miR-206, miR-181a, miR-4538, miR-4539, miR-606,
and miR-454) that were altered in the young DMD patients. As an example, the over-expression of miR-206 in young DMD
patients is predicted to down-regulate a set of target genes (e.g., RHGAP31, KHSRP, CORO1B, PTBP1, C7orf58, DLG4, and
KLF4) that would worsen motor function. Since steroids decreased miR-206 expression to control levels, this could provide one
mechanism by which steroids improve motor function.
Conclusions: These identified microRNA-mRNA alterations will help better understand the pathophysiology of DMD and the
response to steroid treatment.
Keywords: Duchenne muscular dystrophy (DMD), blood, microRNA (miRNA), mRNA (gene)
INTRODUCTION
Duchenne muscular dystrophy (DMD) leads to pro-
gressive weakness of skeletal, respiratory and cardiac
muscles [1, 2]. Increasing evidence shows that inflam-
matory cell infiltration of muscle is an important facet
of disease pathophysiology and is associated with
∗Correspondence to: Dr. Da Zhi Liu, Department of Neurology,
MIND Institute Wet Labs, 2805 50th Street, Sacramento, 95817,
CA, USA. Tel.: +1 916 703 0384; Fax: +1 916 703 0369; E-mail:
dzliu@ucdavis.edu.
disease severity in individual patients [2, 3]. Treat-
ment with prednisone (a steroid) or a derivative
(deflazacort, which produces fewer side effects)
improves muscle strength, prolongs ambulation,
and preserves pulmonary and cardiac function of
patients with DMD [4–9]. However, it is unclear
whether the clinical benefits from steroids relate to
immunosuppressive activity since azathioprine - a non-
steroid-immunosuppressant-failed to improve DMD
[4]. As disordered glycometabolism may be one of
the features of DMD [10, 11], it is possible that the
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clinical benefits from steroid treatment of DMD might
be associated with the regulation of glycometabolism,
since a steroid like prednisone has significant effects
on glucose tolerance in healthy young adults [12].
Whole genome profiling of skeletal muscle as
well as peripheral blood have been used to identify
specific DMD-related cell death and cell regenera-
tion pathways, and monitor gene expression changes
after anti-inflammatory treatment with immunoglobu-
lin, prednisone or deflazacort in patients with DMD
[13–16]. However, the mechanisms that lead to the
changes of mRNA expression remain unclear.
The discovery of microRNAs (miRNA) and their
role as regulators of mRNA expression has led to
new insights as to how gene expression is regulated
[17–20]. Although there are only just over a thousand
miRNAs, each one regulates hundreds of target genes
[21]. More than a third of all human genes may be
regulated by miRNAs [22]. Recently, several blood
miRNAs (such as miR-1, miR-206, miR-133, miR-29,
miR-223, and others) were shown to be differentially
expressed in DMD animal models as well as in DMD
patients [23–32]. In addition to helping account for
changes in mRNA expression, the expression pattern of
miRNAs alone could be biomarkers for prognosis
and/or therapeutic response in DMD.
In this study we performed whole transcriptome
profiling to identify differentially expressed mRNAs
and miRNAs in non-glucocorticoid (steroid) treated
DMD subjects with early stage disease (at pre-
sentation) ages 3–10 years and late stage disease
(non-ambulatory) ages 11–20 years. In addition, we
studied early stage DMD subjects 6 months after start-
ing glucocorticoid (steroid) treatment, as compared
to age, gender and race matched healthy controls.
Potential mRNA-miRNA interactions were studied
using a miRNA target gene algorithm (Target Scan
Human 6.0). We also performed integrated mRNA-
miRNA functional analyses to investigate the possible
networks of differentially expressed mRNAs and
miRNAs using Exploratory Gene Association
Networks (EGAN) [33].
MATERIALS AND METHODS
Study subjects
Patients were recruited from the Comprehen-
sive Neuromuscular Center at Cincinnati Children’s
Hospital Medical Center. The study was approved
by the Institutional Review Board at Cincinnati Chil-
dren’s Hospital Medical Center and was conducted in
accordance with the Declaration of Helsinki. There
were 66 DMD patients (49 patients ages 3 to 10, and
17 patients ages 11 to 20), and 46 healthy controls
(28 healthy controls ages 3 to 10, and 18 healthy
controls ages 11 to 20) (Table 1). Diagnoses were
made by a single board-certified pediatric neurologist
Table 1
Summary patient characteristics data
Cohorts Young DMD patients pre- Older DMD patients Young healthy Older healthy
and post-steroid steroid naı¨ve controls controls
N of subjects 49 17 28 18
N of samples 98 17 28 18
Mean age at enrollment 5.41 ± 1.55 16.33 ± 2.45 6.61 ± 1.93 15.95 ± 3.25
Age range at enrollment 3.16–9.65 12.14–19.95 3.19–9.16 11.96–20.76
Mean age at 2nd blood collection 6.15 ± 1.55 N/A N/A N/A
Mean time period between 0.74 ± 0.26 N/A N/A N/A
2 blood collections
Mean time period b/t 2nd blood draw 0.57 ± 0.12 N/A N/A N/A
and steroid initiation
Mean CK at enrollment 24788 ± 11081 (n = 49) 1368 ± 829 (n = 16∗) 142 ± 75 (n = 27) 160 ± 106 (n = 17)
Mean CK at 2nd blood collection 14717 ± 7555 (n = 47) N/A N/A N/A
BMI at enrollment 16.69 ± 1.49 (n = 48) 20.47 ± 7.70 (n = 15)
BMI at 2nd blood collection 17.1 ± 1.99
Gowers at enrollment (seconds) 2.63 ± 1.19
(range 1.2–7.9)
Gowers at 2nd blood collection (seconds) 1.95 ± 0.68
(range 1.2–5)
30-feet run at enrollment (seconds) 5.32 ± 1.32
(range 3.16–10.41)
30-feet run at 2nd blood collection 4.29 ± 0.76 (n = 48
range 3.1–5.9)
∗One patient with erroneous CK data excluded.
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(B. Wong). The inclusion criteria for subjects for the
study were the diagnosis of DMD with genetic muta-
tional confirmation and/or absent dystrophin in muscle
and a clinical phenotype of DMD with skeletal muscle
(pelvic girdle) weakness with age-appropriate lan-
guage development at the time of diagnosis. Exclusion
criteria were history of any other known medi-
cal disorders, mental retardation or autistic/pervasive
developmental disorders, concurrent illnesses or the
use of other medications or supplements for DMD.
The healthy controls had screening laboratory tests
including CRP, CPK, liver panel and a renal panel
(Table 1). All control subjects had normal CRP, CPK,
liver enzymes and renal function and had no other
known medical conditions.
All subjects were divided into two age ranges:
(1) DMD patients aged 3 through 10 (DMD young,
“DMD-Y”, n = 49); healthy controls aged 3 through
10 (controls young, CTRL-Y, n = 28); and (2) DMD
patients aged 11 through 20 (DMD old, DMD-O,
n = 17) and healthy controls aged 11 through 20 (con-
trols old, CTRL-O, n = 18). One blood sample was
obtained from each subject in the DMD-O group and
healthy controls. Two blood samples were drawn from
each DMD-Y patient, with one prior to steroid treat-
ment (DMD-YpreTx, n = 49), and another 6 months
after initiation of steroid treatment (DMD-YpostTx,
n = 49). The mean duration of steroid treatment for
this group was 0.57 years (Table 1). PAXgene tubes
(PreAnalytiX GmbH, Switzerland) were used to col-
lect blood and stabilize RNA in blood. The tubes were
incubated at room temperature for at least 2 hours, and
then stored frozen at –80◦C until processed.
The protocol yielded five groups: (1) DMD-Y
patients prior to steroid treatment (DMD-YpreTx,
n = 49); (2) DMD-Y patients post initiation of steroid
treatment (DMD-YpostTx, n = 49); (3) healthy con-
trols young (CTRL-Y, n = 28); (4) DMD-O patients
naı¨ve to steroid treatment (DMD-O, n = 17); (5) and
healthy controls old (CTRL-O, n = 18). For all sub-
jects the parents provided informed consent and the
children/adolescents provided either assent or consent.
Total RNA isolation
All blood samples were processed at the same
time and in the same laboratory to reduce technical
variation. Total RNA was isolated according to the
manufacturer’s protocol (PAXgene blood miRNA kit;
PreAnalytiX). RNA quantity and quality were deter-
mined using a Nano-Drop (Thermo Fisher) and Agilent
2100 Bioanalyzer, respectively. Samples required
A260/A280 absorbance ratios ≥1.8, 28 S/18 S rRNA
ratio ≥1.8, and an RNA integrity number (RIN)≥8.
mRNA microarrays
Total RNA (80 ng each sample) was converted
to cDNA and amplified using the Applause WT-
Amp Plus ST System (NuGEN, San Carlos, CA) and
labeled using the FL-Ovation cDNA Biotin Module V2
(NuGEN). The labeled cDNA was then hybridized to
Affymetrix GeneChip Human Gene 1.0 ST microar-
rays (Affymetrix, Santa Clara, CA) to profile gene
expression of mRNAs according to the manufacturer
protocol. High resolution images of the arrays were
obtained and converted to CEL files for analysis.
microRNA arrays
RNA was isolated and 200 ng per subject of total
RNA was used per microarray. RNA was converted to
cDNA and labeled using FlashTag Biotin HSR labeling
kits (Affymetrix, CA) with no amplification. The prod-
uct was hybridized to Affymetrix Gene Chip miRNA
3.0 Arrays (Affymetrix, Santa Clara, CA) and scanned
using an Affymetrix GCS3000 Gene Array Scanner
according to the manufacturer’s protocol.
Statistical analysis of mRNA and miRNA data
Partek Genomics Suite 6.6 (Partek Inc., St. Louis,
MI) was used to analyze mRNA and miRNA. Microar-
ray data were imported into the software with RMA
background correction, quantile normalization and
median polish probeset summarization. No cut-off
filters were used on the expression data. Statistical
analyses on normalized mRNA or miRNA data were
made with three primary comparisons: (1) DMD-
YpostTx (n = 49) versus DMD-YpreTx (n = 49) (paired
t-test); (2) DMD-YpreTx (n = 49) versus CTRL-Y
(n = 28) (unpaired t-test); and (3) DMD-O (n = 17) ver-
sus CTRL-O (n = 18) (unpaired t-test). For the mRNA
data, a P value < 0.05 with a false discovery rate (FDR)
of 5% correction for multiple comparisons with a
fold change > |1.2| cut off was used to identify dif-
ferentially expressed mRNAs. For the miRNA data,
a P < 0.05 coupled with a fold change > |1.2| was con-
sidered significant. The data analyses were performed
by an investigator who was blinded to the groups. The
significantly expressed mRNAs or miRNAs from each
sample were subjected to hierarchical clustering by
Euclidean distance based on their relative expression.
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Custom database of differentially altered miRNAs
and their putative target genes
Target Scan Human 6.0 uses an algorithm that dis-
criminates whether target mRNAs have conserved or
poorly conserved sites for corresponding miRNAs,
using the principle that miRNAs bind to complemen-
tary sequences in the three prime untranslated regions
(3’UTRs) of target mRNAs [18, 34]. Using this algo-
rithm, we generated custom databases comprised of the
over- or under- expressed miRNAs and their putative
target genes (mRNAs), respectively.
Integrated mRNA-miNRA functional analyses
The integrated mRNA-miRNA functional network
analyses were performed according to the method
described previously with minor modifications [33].
Although there are two possible regulatory inter-
actions between mRNAs and miRNA (inverse or
positive), only the inverse mRNA-miRNA interac-
tions were examined because they are the most
common types of interactions and positive interac-
tions are rare (see Discussion). Briefly, data lists
of over/under-expressed mRNAs, and our custom
database of under/over-expressed miRNAs and puta-
tive target genes were uploaded into the integrated
mRNA-miRNA functional network analyses software:
Exploratory Gene Association Networks (EGAN).
The integrated mRNA-miRNA functional networks
were identified and subjected to functional sig-
nificance was assessed using the Gene Ontology
database (GO, Biological Processes). The two pos-
sible pairs of inverse regulatory interactions are
reported in this study including under-expressed
miRNA/over-expressed mRNA or over-expressed
miRNA/under-expressed mRNA.
RESULTS
Patient characteristics
The mean ages for the DMD-Y (n = 49) and DMD-
O (n = 17) patients at enrollment were 5.41 ± 1.55
and 16.33 ± 2.45, respectively. This compares with the
mean age of CTRL-Y (n = 28) group of 6.61 ± 1.93
and CTRL-O (n = 18) of 15.95 ± 3.25. All DMD-Y
and DMD-O subjects were steroid naı¨ve at the time
of enrollment. Each DMD-Y patient received daily
steroid treatment (45 patients were on deflazacort; 4
patients were on predinsone) for an average of 0.57
years before the 2nd blood draw. Steroid treatment in
Table 2
Changes in BMI, CK, Gowers and 30 ft Run at 6 month post-steroid
treatment in DMD-Y group
Post – Pre Direction p-value
(Mean ± SD)
Paired T Signed Rank
BMI 0.41 ± 1.09 Post>Pre 0.0132 0.0322
CK –9849 ± 10054 Post<Pre <0.0001 <0.0001
Gowers (s) –0.68 ± 0.72 Post<Pre <0.0001 <0.0001
30 ft Run (s) –1.01 ± 0.92 Post<Pre <0.0001 <0.0001
DMD-Y patients was associated with improved motor
function in all subjects (Table 2). After steroid treat-
ment, the time for Gowers’ test (timed sit to stand)
decreased from 2.63 ± 1.19 seconds at enrollment to
1.95 ± 0.68 seconds (p < 0.0001); time for 30-feet run
decreased from 5.32 ± 1.32 seconds at enrollment
to 4.29 ± 0.76 seconds (p < 0.0001). CK decreased
from 24788 ± 11081 at enrollment to 14717 ± 7555
(p < 0.0001).
Differentially expressed mRNAs and miRNAs
We measured mRNA and miRNA expression in
blood samples of the five groups (DMD-YpreTx,
n = 49; DMD-YpostTx, n = 49; CTRL-Y, n = 28; DMD-
O, n = 17; and CTRL-O, n = 18) using Affymetrix
GeneChip Human Gene 1.0 ST microarrays and
Affymetrix Gene Chip miRNA 3.0 Arrays. There were
101 mRNAs (FDR < 0.05; fold change > |1.2|) (Fig. 1,
Supplemental Table 1A) and 59 miRNAs (P < 0.05;
fold change > |1.2|) (Supplemental Table 1B) differ-
entially expressed in DMD-YpreTx (n = 49) compared
to CTRL-Y (n = 28). A total of 80 mRNAs (FDR
< 0.05; fold change > |1.2|) (Supplemental Table 2A)
and 17 miRNAs (P < 0.05; fold change > |1.2|) (Sup-
plemental Table 2B) were differentially expressed
in DMD-YpostTx (n = 49) compared to DMD-YpreTx
(n = 49). Though there were no mRNA (FDR < 0.05;
fold change >|1.2|), a total of 95 miRNAs (P < 0.05;
fold change > |1.2|) (Supplemental Table 3) were dif-
ferentially expressed in DMD-O (n = 17) compared to
CTRL-O (n = 18).
Effects of steroid treatment on miRNAs in DMD-Y
patients
Expression of miR-206, miR-181a, miR-4538,
miR-4539 and miR-606 were higher in DMD-Y
(n = 49) patients as compared to CTRL-Y (n = 28),
whereas miR-454 was lower in DMD-Y com-
pared to CTRL-Y (∗P < 0.05 vs. CTRL-Y (n = 28).
Steroid treatment (DMD-YpostTx, n = 49) reversed the
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Fig. 1. Hierarchical clustering of 101 mRNAs (FDR <0.05, fold change > |1.2|) that were differentially expressed in the comparison of DMD-
YpreTx (n = 49) and CTRL-Y (n = 28). Statistical differences were determined using unpaired t-test. Red = up-regulation; white = no change;
blue = down-regulation.
Fig. 2. Steroid treatment reversed expression patterns of several
miRNAs (miR-206, miR-181a, miR-4538, miR-4539, miR-606, and
miR-454) that were altered in young DMD patients as compared
to young healthy controls (∗P < 0.05 vs. CTRL-Y; #P < 0.05 vs.
DMD-YpreTx).
expression patterns of these miRNAs at the post-
treatment time point, decreasing the over-expressed
miR-181a, miR-4538, miR4539, miR-206 and miR-
606, and increasing the under-expressed miR-454
to control levels (#P < 0.05 vs. DMD-YpreTx, n = 49)
(Fig. 2, Supplemental Table 4).
Functional analysis of under-expressed mRNAs
and over-expressed miRNAs in DMD-YpreTx
compared to CTRL-Y
In the comparison of DMD-YpreTx (n = 49) and
CTRL-Y (n = 28), the integrated mRNA-miRNA
functional analyses showed the links between
the under-expressed mRNAs (PSAP, CTNND1,
GLT25D1, PLD3, AGPAT3, SLC27A4, RPS6KA4,
CD4, DPYSL2, DLG4, VASH1, GFRA2, GLTSCR1,
TTYH3, KLF4, HDC, RAB34, CBX6, PTBP1,
SEPN1, CORO1B, and others) and the over-expressed
miRNAs (miR-206, miR-181a, miR-4538, miR4539,
miR-548c-3p, miR-509-3-5p) (Fig. 3). The top
canonical pathways of this mRNAs-miRNA network
included locomotion/ motor function (p = 4.79E-04),
lipid metabolic process (p = 4.95E-04), induction by
virus of host cell-cell fusion (p = 6.85E-04), protein
palmitolylation (p = 6.85E-04) and others (Fig. 3). We
could not perform miRNA-mRNA functional analysis
on the over-expressed mRNAs because there were no
over-expressed mRNAs in this comparison.
Functional analysis of under-expressed mRNAs
and over-expressed miRNAs in DMD-YpostTx
compared to DMD-YpreTx
In the comparison of DMD-YpostTx (n = 49) and
DMD-YpreTx (n = 49), the integrated mRNA-miRNA
functional analyses showed links between the under-
expressed mRNAs (ARID5B, COL19A1, CXCR5,
BCL11A, ENPP2, FMNL3, KCNH8, BTBD3, TCF4,
PDE7B, GGA2, PCDH9, BACH2, MOBKL2B,
PMEPA1, AFF3) and the over-expressed miRNAs
(miR-454, miR-4745-5p, miR-1303) (Fig. 3). The
top canonical pathways of this mRNAs-miRNA
network included B cell activation (p = 9.14E-04),
phosphatidylcholine catabolic process (p = 1.06E-03),
fibroblast migration (p = 1.41E-03), muscle organ
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Fig. 3. Integrated mRNA-miRNA functional analysis showing the network between under-expressed mRNAs and over-expressed miRNAs in
DMD-YpreTx as compared to CTRL-Y, and associated functions (such as locomotion) of the mRNAs-miRNAs network.
Fig. 4. Integrated mRNA-miRNA functional analysis showing the network between under-expressed mRNAs and over-expressed miRNAs in
DMD-YpostTx as compared to DMD-YpreTx, and associated functions (such as muscle organ development) of the mRNAs-miRNAs network.
development (p = 2.96E-03), lymph node development
(p = 3.53E-03) and others (Fig. 4).
Functional analysis of over-expressed mRNAs and
under-expressed miRNAs in DMD-YpostTx
compared to DMD-YpreTx
In the comparison of DMD-YpostTx (n = 49) and
DMD-YpreTx (n = 49), the integrated mRNA-miRNA
functional analyses showed links between the over-
expressed mRNAs (GRB10, CD163, FLT3, FKBP5,
CDC14B, NETO1, ERG, ASPH, MMP8) and the
under-expressed miRNAs (miR-206, miR-181a, miR-
4538, miR4539, miR-409-3p, miR-4478, miR-1279)
(Fig. 4). The top canonical pathways of this mRNAs-
miRNA network included vascular endothelial growth
factor receptor signaling pathway (p = 1.74E-05), neg-
ative regulation of glycogen biosynthetic process
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Fig. 5. Integrated mRNA-miRNA functional analysis showing the network between over-expressed mRNAs and under-expressed miRNAs
in DMD-YpostTx as compared to DMD-YpreTx, and associated functions (such as regulation of glucose metabolism) of the mRNAs-miRNAs
network.
(p = 5.96E-04), activation of anaphase-promoting
complex activity (p = 9.94E-04), negative regulation of
glycogen metabolic process (p = 9.94E-04), negative
regulation of glucose import (p = 1.39E-03), nega-
tive regulation of glucose transport (p = 1.59E-03) and
others (Fig. 5).
DISCUSSION
This study demonstrated numerous mRNAs and
miRNAs, including some muscle-specific miRNAs
(e.g., miR-206) previously reported by others [25–32],
were altered significantly in the whole blood of young
DMD patients (age 3–10, n = 49) as compared to
young healthy controls (age 3–10, n = 28). Notably, no
mRNAs but 95 miRNAs were significantly altered in
old DMD patients (age 11–20, n = 17) as compared to
old healthy controls (age 11–20, n = 18). The data also
showed that steroid treatment attenuated the changes
of several miRNAs (miR-206, miR-181a, miR-4538,
miR-4539, miR-606, and miR-454) that were altered
in young DMD patients (n = 49) before treatment com-
pared to controls.
A recent study showed that DMD patients with
milder disease have higher levels of muscle-specific
miRNAs (e.g., miR-1, miR-206, miR-133) in blood
than more severely affected patients [23]. This suggests
that the expression abundance of muscle-specific miR-
NAs in blood varies depending on the severity of DMD.
Our results confirm this suggestion in that miR-206 and
miR-133 were both regulated in young DMD patients.
In addition, miR-206 has also been implicated in other
muscle disorders like muscle hypertrophy [35, 36].
There are two potential modes of miRNA regulation
of target mRNAs. One is known as inverse/negative
regulation by which miRNAs bind to complementary
sequences in the 3’UTRs of target mRNAs, resulting in
transcript degradation and post-translational suppres-
sion [18, 34, 37–39]. Another is positive regulation
in which miRNAs bind to the non-coding regula-
tory regions in gene promoters, sometimes leading
to transcriptional and translational activation [40–43].
Here, we focused only on negative regulation in the
mRNA-miRNA functional network analyses because
mRNA-miRNA negative regulation is much more
prevalent than positive regulation, and available algo-
rithms for predicting target mRNAs of the miRNAs
are currently based upon the principle of negative
regulation.
Although it was unknown of the exact cells/origins
of the mRNA or miRNA as we measured from a
whole blood composite, we thought it was important to
address the regulatory interactions and relationships of
these two classes of RNA as cell localization of miRNA
does not limit the ability to cross transport through
vesicles/exosomes and interact with other cells. The
integrated mRNA-miRNA functional network analy-
ses showed that: (1) in young DMD patients (n = 49)
vs. healthy controls (n = 28), under-expressed mRNAs
and over-expressed miRNAs were related to loco-
motor/motor function and (2) in post-steroid young
DMD patients (n = 49), under-expressed mRNAs and
over-expressed miRNAs were associated with mus-
cle organ development and B cell activation, while
over-expressed mRNAs and under-expressed miRNAs
were associated with glycogen metabolism and glu-
cose transport.
Our data showed that miR-206 was over-expressed
significantly in young DMD patients but not in older
DMD patients. This is consistent with previous reports
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that miR-206 increased in blood at the early stage
of disease and resolved at a later stage over time
in the mouse DMD model [25]. Although the over-
expression of miR-206 in blood has been reported
in DMD [25–32], we are the first to demonstrate
the decrease of miR-206 after steroid treatment in
young DMD patients. Furthermore, the integrated
mRNA-miRNA functional network analysis revealed
that over-expressed miR-206 would down-regulate a
set of potential target genes (e.g., RHGAP31, KHSRP,
CORO1B, PTBP1, C7orf58, DLG4, and KLF4) that
affect motor function such that the over expressed
miR-206 would worsen locomotion/motor function.
Therefore, the decrease in miR-206 after steroid treat-
ment would up-regulate the above target genes which
would tend to improve skeletal muscle function and
preserve pulmonary and cardiac function.
We also identified five more miRNAs, including
miR-181a, miR-4538, miR-4539, miR-606, and miR-
454, that were associated with steroid treatment in the
young DMD patients. miR-206, miR-181a, miR-4538,
miR-4539 and miR-606 were elevated in young DMD
patients, but decreased to control levels after steroid
treatment. Interestingly, many predicted functions of
over-expressed mRNAs and under-expressed miRNAs
after steroid treatment were associated with glycogen
metabolism and glucose transport. This suggests a pos-
sible glycogen/glucose mechanism by which steroid
treatment improves muscle function of DMD patients,
as disrupted glycometabolism has been proposed to
be a feature of DMD [10, 11]. Though miR-454 was
decreased in young DMD patients compared to con-
trols, it increased following steroid treatment. The
integrated mRNA-miRNA functional network analy-
sis showed that over-expressed miR-454 after steroid
treatment might down-regulate a set of target genes
(e.g., MOBKL2B, GGA2, AFF3, BACH2, COL19A1,
PMEPA1, TCF4, BCL11A, PDE7B, FMNL3, BTBD3,
KCNH8, and ARID5B) which are associated with
muscle and immune cell development. Thus, steroids
might suppress immune function but at the same time
interfere with muscle development. However, it is
unclear if the up-regulation of miR-454 after steroid
treatment is beneficial or detrimental, as the changes
in glycogen and glucose metabolism could either be
favorable or damaging indicators for DMD or treat-
ment progression.
Our data provides a library of possible mRNA-
miRNA networks in blood that may provide insight
into the molecular basis for disease mechanisms in
DMD and biological pathways associated with the
pharmacological response of steroid therapy in DMD.
Future studies might compare blood of DMD patients
to Becker’s and other muscular dystrophies to deter-
mine if there are specific leukocyte responses to each.
Indeed, one of the DMD patients in this study was
later diagnosed as Becker’s, though the blood mRNA-
miRNA profile of this Becker’s patient was most like
that of the controls than the DMD patients. Thus,
even different genetic mutations in the dystrophin gene
might produce different mRNA-miRNA responses
which will require further study. Moreover, future stud-
ies will need to focus on the steroid responsive miRNAs
(i.e., miR-206, miR-181a, miR-4538, miR-4539, miR-
606, and miR-454) to examine which cell type(s) they
are derived from and how they interact with blood
leukocytes with or without steroid treatment in DMD.
There are some limitations of this study, including 1)
Sample size of old DMD patients (n = 18) was small; 2)
Lack of knowledge of the cell types expressing either
the mRNA or miRNAs identified, and whether they
were derived from muscle, white cells or other tissues;
3) Lack of validation of the transcript expression data
by a second method (e.g. qRT-PCR); 4) Challenges
in assigning steroid-responsive miRNAs as biomark-
ers of either efficacy or toxicity; 5) The utilization
of relatively non-stringent statistical adjustments for
multiple testing (particularly with miRNA analyses)
suggests that some may be false positives, and should
be validated in future independent data sets.
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